Recs

3

3 Stocks Springing Back

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

With all the volatility in the markets today, there's no shortage of market seers attempting to call a bottom. Man of the Year Ben Bernanke called a bottom not once, but twice. Heck, even Keanu Reeves laid out what a world-ending market bottom looks like.

Investors should consider buying stocks after a big decline, when pessimism has unduly beaten good companies down to great prices. That's why we here at the Fool -- and 160,000-plus investors like us -- look to the Motley Fool CAPS community to help sniff out the real opportunities from languishing companies driven by speculation.

A real bottom or another leg down?
Of course, there's no foolproof method for timing a market bottom. But CAPS has a great balance of both quantitative and qualitative resources available on 5,400 stocks, and even a nifty stock screening tool to help investors quickly zero in on potential investment opportunities.

I've used the CAPS screener to filter out $100 million-plus companies that have seen their stock price appreciate by at least 20% in the past 13 weeks even while they remain at least 30% below their 52-week high.

Company

CAPS Rating
(out of 5)

13-Week
Price Change

% Below 52-Week High

Excel Maritime Carriers (NYSE: EXM  )

*****

31.4%

40.6%

Rexahn Pharmaceuticals (NYSE: RNN  )

*

171.4%

48.4%

Novavax (Nasdaq: NVAX  )

*

23.4%

64.8%

Source: Motley Fool CAPS. Results from Feb. 5 through May 4.

Investors have been more willing to buy into Novavax recently as the company has been making progress in clinical trials with its flu vaccine. And while shares of Rexahn Pharmaceuticals have been swinging wildly as the market digests mixed messages from results of a mid-stage trial of Serdaxin, the recent share movements in these stocks have done little to move CAPS members collective opinion on these clinical stage biopharmaceutical companies, which still sit at a lowly one-star rating each. On the flip side, plenty of members think Excel Maritime Carriers may be seeing a legitimate move higher.             

The bottom case
With a five-star rating in CAPS, members see several reasons why Excel Maritime Carriers may be looking nowhere but up today. A number of investors believe the stock is trading at a big discount relative to its book value, which could help drive the stock higher, especially if a recovery of the dry bulk sector gets under way. Dry bulk shipping rates have recently seen some renewed strength, which -- if the trend continues -- bodes well for Excel Maritime and Genco Shipping & Trading (NYSE: GNK  ) that have high exposure to the spot market. Genco has started strong out of the gate, having booked multiple new time charters in the first quarter, helping to bring about two-thirds of its fleet's available days under contract for this year. And one Oppenheimer analyst sees potential further upside in day rates when Chinese iron ore contracts become finalized, leading to increased imports into China and a possible boost to the entire dry bulk sector.

Or further to fall?
Even though Excel Maritime Carriers shows a glass half full to many investors, the looming issue of overcapacity in the dry bulk sector remains a threat to a robust recovery. Paragon Shipping (NYSE: PRGN  ) is committed to adding four new builds spread across 2011 and 2012, with options for four more in 2012 as well. Navios Maritime (NYSE: NM  ) recently added a Capesize vessel to its fleet and agreed to acquire another one. With many investors and analysts long showing concern about a shipping supply glut, the announcements of more ships in play is not encouraging to many who still see demand uncertainty. Some investors also remain concerned over the heavy debt loads of Excel and others like Dryships (Nasdaq: DRYS  ) , which had nearly $3 billion at the end of last year and recently visited the debt markets for more. While Excel's debt is smaller than Dryships', it still dwarfs its market cap. And with some of these lingering issues adding more uncertainty, some investors see better options in other companies.

What's your call?
Overall, 96% of the 1,925 CAPS members rating Excel Maritime Carriers are bullish and see it outperforming the broader market. For my part, it takes an awful lot to overlook heavy debt loads, so I tend to prefer cleaner balance sheets backing up a stock.

But what ultimately counts is your own opinion; CAPS is just there to help you form it. The best part is that the Motley Fool CAPS database is all free, and you can even add your own insight on any of the 5,400 stocks that our 160,000-plus members have covered.

The Steve Jobs Betrayal
You may already know that in the final year of his life, Jobs revealed a stunning betrayal — and told his biographer, "I will spend my last dying breath... and every penny of Apple's $40 billion in the bank to right this wrong." What was it that made Jobs so irate — and why could it make a few in-the-know investors some major profits over the coming months and years?

Enter your email address below to find out what made Jobs so enraged!

The Motley Fool Stock Advisor service looks for companies with strong management poised to beat the market over the long haul. To see all the stocks that have helped Tom and David Gardner beat the market by 60 points on average, take a free 30-day trial.

Since getting some new sneakers, Fool contributor Dave Mock is showing a little more spring in his step too. He owns no shares of companies mentioned here. The Fool's disclosure policy sometimes gets wound too tight and needs a deep-tissue massage.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 07, 2010, at 10:07 AM, Louiethelooper wrote:

    RNN should be rated higher than one-star. News about its ED drug, Zoraxel, is due out shortly and are expected to be positive.

    The Dow got dumped on yesterday, yet RNN rllied over the $2 benchmark again.

    RNN already has a partnership with Tiva that comes with milestone cash infusions. I believe other partnerships will be announced by year's end.

    All in all, RNN has a bright future. Too bad the impatient ones among us pan it from time to time because it didn't skyrocket to $10 in a week.

    Sometimes, the expectations of some are really way over the top. I'll settle for a nice and steady rise to $10, ony I know it might take a year and not a week.

    I rate RNN a strong buy.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 1175969, ~/Articles/ArticleHandler.aspx, 5/26/2012 12:37:07 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 12,454.83 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
NASD 2,837.53 -1.85 -0.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/25/2012 4:02 PM
EXM $0.89 Down -0.02 -2.21%
Excel Maritime Car… CAPS Rating: ****
NM $3.48 Up +0.14 +4.19%
Navios Maritime Ho… CAPS Rating: *****
NVAX $1.27 Up +0.02 +1.60%
Novavax, Inc. CAPS Rating: *
DRYS $2.29 Up +0.04 +1.78%
DryShips, Inc. CAPS Rating: ***
GNK $3.22 Up +0.25 +8.42%
Genco Shipping & T… CAPS Rating: ***

Advertisement